Top Markets
Coin of the day
Clarity Pharmaceuticals Ltd Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

CU6
株式のランク #11775
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company,... Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
株価
$1.77
最終同期: 2026-08-28
時価総額
$660.45M
変化(1日)
7.26%
変化(1年)
-9.15%
AU
取引 Clarity Pharmaceuticals Ltd (CU6)

カテゴリー

Clarity Pharmaceuticals Ltd(CU6)の配当利回りの履歴
Clarity Pharmaceuticals Ltd(銘柄コード: CU6)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Clarity Pharmaceuticals Ltd(CU6)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)